Heron Therapeutics Inc banner

Heron Therapeutics Inc
NASDAQ:HRTX

Watchlist Manager
Heron Therapeutics Inc Logo
Heron Therapeutics Inc
NASDAQ:HRTX
Watchlist
Price: 0.9567 USD 2.09% Market Closed
Market Cap: $180.4m

Multiples-Based Value

The Multiples-Based Value of one HRTX stock under the Base Case scenario is 2.9677 USD. Compared to the current market price of 0.9567 USD, Heron Therapeutics Inc is Undervalued by 68%.

Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

HRTX Multiples-Based Value
2.9677 USD
Undervaluation 68%
Multiples-Based Value
Price $0.9567
Worst Case
Base Case
Best Case

Multiples Across Competitors

HRTX Competitors Multiples
Heron Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Heron Therapeutics Inc
NASDAQ:HRTX
180.2m USD 1.2 -8.9 -1 224 -108
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 690 872.8 -160 127.7 -194 446.1 -192 227.3
US
Abbvie Inc
NYSE:ABBV
368.5B USD 6 88 14.6 20.3
US
Amgen Inc
NASDAQ:AMGN
187.7B USD 5.1 24.3 14.1 14.1
US
Gilead Sciences Inc
NASDAQ:GILD
173.5B USD 5.9 20.4 12.7 15.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
112.2B USD 9.3 28.4 21.3 22.3
US
Epizyme Inc
F:EPE
94.1B EUR 2 091 -533.6 -581 -565.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.7B USD 5.6 17.7 13.1 15
NL
argenx SE
XBRU:ARGX
43.9B EUR 12.4 39.7 43.1 44
AU
CSL Ltd
ASX:CSL
67.2B AUD 2.9 32.4 10.9 13.8
US
Seagen Inc
F:SGT
39.3B EUR 20.1 -61.8 -66.6 -60.1
P/S Multiple
Revenue Growth P/S to Growth
US
Heron Therapeutics Inc
NASDAQ:HRTX
Average P/S: 3 063 002.9
1.2
19%
0.1
FR
Pharnext SCA
OTC:PNEXF
33 690 872.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
5.1
3%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
5.9
5%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.3
11%
0.8
US
E
Epizyme Inc
F:EPE
2 091
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.6
10%
0.6
NL
argenx SE
XBRU:ARGX
12.4
28%
0.4
AU
CSL Ltd
ASX:CSL
2.9
4%
0.7
US
S
Seagen Inc
F:SGT
20.1
30%
0.7
P/E Multiple
Earnings Growth PEG
US
Heron Therapeutics Inc
NASDAQ:HRTX
Average P/E: 35.9
Negative Multiple: -8.9
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 127.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
88
97%
0.9
US
Amgen Inc
NASDAQ:AMGN
24.3
20%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
20.4
16%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
28.4
19%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -533.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.7
14%
1.3
NL
argenx SE
XBRU:ARGX
39.7
30%
1.3
AU
CSL Ltd
ASX:CSL
32.4
9%
3.6
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.8 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Heron Therapeutics Inc
NASDAQ:HRTX
Average EV/EBITDA: 18.6
Negative Multiple: -1 224
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 446.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
14.6
12%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.1
10%
1.4
US
Gilead Sciences Inc
NASDAQ:GILD
12.7
9%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21.3
18%
1.2
US
E
Epizyme Inc
F:EPE
Negative Multiple: -581 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.1
17%
0.8
NL
argenx SE
XBRU:ARGX
43.1
49%
0.9
AU
CSL Ltd
ASX:CSL
10.9
7%
1.6
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.6 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Heron Therapeutics Inc
NASDAQ:HRTX
Average EV/EBIT: 20.7
Negative Multiple: -108
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 227.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
20.3
23%
0.9
US
Amgen Inc
NASDAQ:AMGN
14.1
3%
4.7
US
Gilead Sciences Inc
NASDAQ:GILD
15.7
13%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.3
17%
1.3
US
E
Epizyme Inc
F:EPE
Negative Multiple: -565.5 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15
23%
0.7
NL
argenx SE
XBRU:ARGX
44
51%
0.9
AU
CSL Ltd
ASX:CSL
13.8
10%
1.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.1 N/A N/A
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett